A single-center study investigated 133 patients with relapsed and/or refractory CD19+ B-cell acute lymphatic leucemia, non-Hodgkin lymphoma, and chronic lymphoid lymphoma who received CD19-CAR-T cell therapy (155). The gene discussed is CD19; the disease is non-Hodgkin lymphoma.